SSA
PRDS

Schonfeld Strategic Advisors’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio PRDS Stock Details PRDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-27,209
Closed -$271K – 2677
2021
Q3 		$271K Buy
+27,209
New +$270K ﹤0.01% 1584

Other funds holding PRDS

FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
FCOMV
Foresite Capital Opportunity Management V Larkspur, California $33.3M AUM 47.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
JCM
JS Capital Management New York $109M AUM 34.13% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Schonfeld Strategic Advisors's PRDS Position: Q4 2021 in Review

Schonfeld Strategic Advisors sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q4 2021, closing a stake of 27,209 shares — an estimated $271K sold.

Schonfeld Strategic Advisors first reported a position in PRDS in Q3 2021 and held it in 1 quarter. The position peaked at $271K in Q3 2021. 41 funds tracked by Wall St. Rank hold PRDS as of Q4 2021.

  • Schonfeld Strategic Advisors reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 27,209 Pardes Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $271K.
  • Schonfeld Strategic Advisors first reported a position in Pardes Biosciences, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's Pardes Biosciences, Inc. Common Stock position peaked at $271K in Q3 2021.
  • 41 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q4 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.